96 related articles for article (PubMed ID: 25468813)
21. Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid.
Hayashi N; Furihata M; Ohtsuki Y; Ueno H
Virchows Arch; 1994; 424(5):503-9. PubMed ID: 8032531
[TBL] [Abstract][Full Text] [Related]
22. UV-independent p53 mutations in sebaceous carcinoma of the eyelid.
Hussain RM; Matthews JL; Dubovy SR; Thompson JM; Wang G
Ophthalmic Plast Reconstr Surg; 2014; 30(5):392-5. PubMed ID: 24777261
[TBL] [Abstract][Full Text] [Related]
23. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
[TBL] [Abstract][Full Text] [Related]
24. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
25. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
26. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
27. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
28. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
30. [HER2 gene amplification and overexpression in advanced gastric cancer].
Roa I; Slater J; Carvajal D; Schalper K; de Toro G; Ares R; Game A; León J; de Aretxabala X
Rev Med Chil; 2013 Nov; 141(11):1411-9. PubMed ID: 24718467
[TBL] [Abstract][Full Text] [Related]
31. ZEB2/SIP1 as novel prognostic indicator in eyelid sebaceous gland carcinoma.
Bhardwaj M; Sen S; Sharma A; Kashyap S; Chosdol K; Pushker N; Bajaj MS; Bakhshi S
Hum Pathol; 2015 Oct; 46(10):1437-42. PubMed ID: 26220160
[TBL] [Abstract][Full Text] [Related]
32. HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status.
Nakano T; Yamamoto H; Hashimoto K; Tamiya S; Shiratsuchi H; Nakashima T; Nishiyama K; Higaki Y; Komune S; Oda Y
Histopathology; 2013 Sep; 63(3):378-92. PubMed ID: 23855785
[TBL] [Abstract][Full Text] [Related]
33. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
Pellegrini C; Falleni M; Marchetti A; Cassani B; Miozzo M; Buttitta F; Roncalli M; Coggi G; Bosari S
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3645-52. PubMed ID: 14506153
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.
Sekido Y; Umemura S; Takekoshi S; Suzuki Y; Tokuda Y; Tajima T; Osamura RY
Int J Oncol; 2003 Jun; 22(6):1225-32. PubMed ID: 12738987
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
37. Gene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinoma.
López F; Llorente JL; Oviedo CM; Vivanco B; Marcos CÁ; García-Inclán C; Scola B; Hermsen MA
Cancer; 2012 Apr; 118(7):1818-26. PubMed ID: 22009799
[TBL] [Abstract][Full Text] [Related]
38. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
[TBL] [Abstract][Full Text] [Related]
39. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
[TBL] [Abstract][Full Text] [Related]
40. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]